SCHEMBL25845893

SCHEMBL25845893

CCCCOC(=O)C1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGMN Q99538 2/20 0.55
MAPT P10636 7/20 0.53
LMNA P02545 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
TSHR P16473 1/20 0.49
CYP2C19 P33261 1/20 0.49
PDE4D Q08499 1/20 0.49
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
TP53 P04637 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
KMT2A Q03164 1/20 0.48
RELA Q04206 1/20 0.48
SHMT2 P34897 1/20 0.44
ALDH1A1 P00352 3/20 0.44
HSP90AA1 P07900 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30919898 0.91 MAPT (0.48) LGMNMAPTLMNACYP1A2CYP3A4
SCHEMBL27543 0.87 LGMN (0.70) LGMNMAPTKMT2ASHMT2ALDH1A1
SCHEMBL25845895 0.83 MAPT (0.78) LGMNMAPTLMNACYP2C9CYP2C19
SCHEMBL30193146 0.81 LMNA (0.45) LGMNMAPTLMNACYP1A2CYP3A4
SCHEMBL16611364 0.79 MAPT (0.66) LGMNMAPTLMNASMN1; SMN2TP53
SCHEMBL17250906 0.78 HTT (0.53) LGMNMAPTLMNANPC1RAB9A
Hydrochloric Acid SCHEMBL31540771 0.78 MAPT (0.57) MAPTLMNACYP1A2CYP3A4CYP2C9
SCHEMBL27542358 0.78 LMNA (0.47) MAPTLMNACYP1A2CYP3A4CYP2C9
SCHEMBL13624224 0.77 MAPT (0.48) LGMNMAPTLMNACYP1A2CYP3A4
SCHEMBL5725223 0.77 SMN1; SMN2 (0.51) LGMNMAPTCYP2C19NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 LGMN 2118/4885MAPT 1277/4885LMNA 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.